IFP Advisors’s Theravance Biopharma TBPH Stock Holding History

IFP Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51	Hold	3	–	–	﹤0.01%	5021
2026 Q1	$49	Hold	3	–	–	﹤0.01%	4833
2025 Q4	$56	Hold	3	–	–	﹤0.01%	4686
2025 Q3	$44	Buy	+3	New	+$38	﹤0.01%	4677
2025 Q2	–	Hold	0	–	–	–	4304
2025 Q1	–	Sell	-32	Closed	-$298	–	4132
2024 Q4	$357	Buy	+32	New	+$291	﹤0.01%	3511
2019 Q1	–	Sell	-57	Closed	-$1K	–	3322
2018 Q4	$1K	Hold	57	–	–	﹤0.01%	3382
2018 Q3	$2K	Hold	57	–	–	﹤0.01%	3578
2018 Q2	$1K	Hold	57	–	–	﹤0.01%	3772
2018 Q1	$2K	Hold	57	–	–	﹤0.01%	3544
2017 Q4	$2K	Hold	57	–	–	﹤0.01%	3595
2017 Q3	$2K	Hold	57	–	–	﹤0.01%	3794
2017 Q2	$2K	Hold	57	–	–	﹤0.01%	3770
2017 Q1	$2K	Hold	57	–	–	﹤0.01%	3694
2016 Q4	$2K	Hold	57	–	–	﹤0.01%	3678
2016 Q3	$2K	Hold	57	–	–	﹤0.01%	3619
2016 Q2	$1K	Buy	+57	New	+$1.23K	﹤0.01%	3680
2016 Q1	–	Sell	-57	Closed	-$1K	–	3331
2015 Q4	$1K	Buy	+57	New	+$905	﹤0.01%	3561

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

IFP Advisors's TBPH Position: Q2 2026 in Review

IFP Advisors held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 3 shares worth $51. The position accounts for ﹤0.01% of the portfolio, ranked #5021.

IFP Advisors first reported a position in TBPH in Q4 2015 and has held it in 17 quarters since. The position peaked at $2K in Q3 2018. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

IFP Advisors held 3 shares of Theravance Biopharma worth $51 as of Q2 2026.
IFP Advisors left its Theravance Biopharma share count unchanged in Q2 2026.
Theravance Biopharma made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5021 holding.
IFP Advisors first reported a position in Theravance Biopharma in Q4 2015 and has held it in 17 quarters since.
IFP Advisors's Theravance Biopharma position peaked at $2K in Q3 2018.
179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.